BeiGene Receives Positive CHMP Opinion for BRUKINSA^® (Zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of BRUKINSA® for the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.